Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Astellas Pharma

ALPMFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$9.70

At close: Mar 12, 9:18 AM EDT

$10.87

1.1712.07%

After Hours: Mar 12, 9:18 AM EDT

Astellas Pharma (ALPMF) Forecast

News

Earnings Astellas Pharma (ALPMF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Astellas Pharma (OTC:ALPMF) Stock

Astellas Pharma Stock (OTC: ALPMF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, February 11, 2025

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Vandana Singh

Friday, January 03, 2025

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
Vandana Singh

Tuesday, December 31, 2024

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Vandana Singh

Wednesday, October 16, 2024

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Vandana Singh

Monday, August 05, 2024

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Vandana Singh

Friday, May 17, 2024

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Vandana Singh

Friday, November 17, 2023

Astellas Pharma And Pfizer Announced FDA Appr...
Benzinga Newsdesk

Thursday, October 05, 2023

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Vandana Singh

Friday, September 22, 2023

Why Is Seagen Stock Trading Higher Today?
Vandana Singh

Wednesday, September 20, 2023

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Vandana Singh

Wednesday, August 23, 2023

Pfizer And Astellas Pharma Report FDA Grants ...
Benzinga Newsdesk

Thursday, July 06, 2023

On July 6, At Special Meeting Iveric Bio Inc Board Of Directors Approved Merger Proposal With Astellas Pharma
Happy Mohamed

Thursday, June 08, 2023

Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Vandana Singh

Tuesday, May 30, 2023

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
David Willey - Sponsored

Monday, May 15, 2023

Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Vandana Singh
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
Vandana Singh

Monday, May 01, 2023

Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Vandana Singh
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Vandana Singh

Tuesday, April 04, 2023

FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Vandana Singh

Tuesday, March 28, 2023

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Vandana Singh

Monday, March 27, 2023

Japanese Government Urges China To Release Astellas Pharma's Employee
Vandana Singh

Friday, March 17, 2023

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Vandana Singh

Tuesday, January 31, 2023

Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Vandana Singh

Tuesday, January 24, 2023

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Vandana Singh

Tuesday, October 25, 2022

Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Vandana Singh

Thursday, August 18, 2022

Astellas' Menopause Drug Under FDA Review
Vandana Singh

Tuesday, July 26, 2022

Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Vandana Singh
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Vandana Singh
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Vandana Singh

Tuesday, June 28, 2022

The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Vandana Singh
Sutro Biopharma Stock Surges On Cancer Treatment Pact
Vandana Singh

Monday, June 27, 2022

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Vandana Singh
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
Vandana Singh

Monday, May 09, 2022

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
Vandana Singh

Wednesday, April 13, 2022

Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
Vandana Singh

Tuesday, March 15, 2022

Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
Vandana Singh

Monday, March 07, 2022

Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
Vandana Singh

Tuesday, February 15, 2022

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Vandana Singh

Thursday, December 02, 2021

Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Vandana Singh

Monday, September 27, 2021

Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Vandana Singh

Tuesday, September 14, 2021

Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Vandana Singh

Wednesday, September 01, 2021

See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Vandana Singh

Friday, August 20, 2021

After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Vandana Singh

Wednesday, August 11, 2021

FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Vandana Singh

Monday, July 19, 2021

Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data
Vandana Singh

Monday, July 12, 2021

Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
Vandana Singh

Tuesday, May 11, 2021

Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Vandana Singh

Monday, May 03, 2021

Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Vandana Singh

Tuesday, April 27, 2021

Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold
Vandana Singh

Wednesday, April 07, 2021

FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Vandana Singh

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved